Pharmacokinetics of cefodizime administered intravenously as a single-dose (1.0 and 2.0 g) to healthy adult volunteers. 1990

A Bryskier, and T Procyk, and D Tremblay, and B Lenfant, and J B Fourtillan
Institut Roussel-Uclaf, Romainville, France.

Cefodizime is a new third generation cephalosporin for parenteral use. The purpose of this study was to define the pharmacokinetic profile of cefodizime after intravenous dosing with 1.0 and 2.0 g in healthy adult volunteers. Concentrations in plasma were determined over a period of 34 h and in urine over 48 h, using high-pressure liquid chromatographic procedures. Cefodizime displays a long elimination half-life (3.5-3.7 h). Mean total clearance was 2.63 +/- 0.19 l/h and mean renal clearance was 1.37 +/- 0.15 l/h. Areas under the curve were 422 +/- 43 mg.h/l and 757 +/- 39 mg.h/l for 1.0 and 2.0 g respectively. The apparent volumes of distribution were 12.8 +/- 1.81 and 14.3 +/- 1.11. After 1.0 g administration the residual concentrations were 3.94 +/- 0.79 mg/l and 0.38 +/- 0.10 mg/l at 12 and 24 h, respectively; after 2.0 g administration the residual concentrations were 6.80 +/- 1.40 mg/l and 0.65 +/- 0.18 mg/l, at 12 h and 24 h. Cefodizime is mainly eliminated via the kidneys. This profile supports once-daily administration of cefodizime, when indicated in non-life-threatening infections.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D002439 Cefotaxime Semisynthetic broad-spectrum cephalosporin. Benaxima,Biosint,Cefotaxim,Cefotaxime Sodium,Cefradil,Cephotaxim,Claforan,Fotexina,HR-756,Kendrick,Klaforan,Primafen,Ru-24756,Taporin,HR 756,HR756,Ru 24756,Ru24756,Sodium, Cefotaxime
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

A Bryskier, and T Procyk, and D Tremblay, and B Lenfant, and J B Fourtillan
September 1995, Antimicrobial agents and chemotherapy,
A Bryskier, and T Procyk, and D Tremblay, and B Lenfant, and J B Fourtillan
August 1985, Antimicrobial agents and chemotherapy,
A Bryskier, and T Procyk, and D Tremblay, and B Lenfant, and J B Fourtillan
January 1986, Haemostasis,
A Bryskier, and T Procyk, and D Tremblay, and B Lenfant, and J B Fourtillan
January 1984, Therapie,
A Bryskier, and T Procyk, and D Tremblay, and B Lenfant, and J B Fourtillan
July 2017, Acta anaesthesiologica Scandinavica,
A Bryskier, and T Procyk, and D Tremblay, and B Lenfant, and J B Fourtillan
March 2017, Journal of clinical pharmacology,
A Bryskier, and T Procyk, and D Tremblay, and B Lenfant, and J B Fourtillan
March 2010, Clinical and experimental pharmacology & physiology,
A Bryskier, and T Procyk, and D Tremblay, and B Lenfant, and J B Fourtillan
November 1983, Antimicrobial agents and chemotherapy,
A Bryskier, and T Procyk, and D Tremblay, and B Lenfant, and J B Fourtillan
January 1987, Infection,
A Bryskier, and T Procyk, and D Tremblay, and B Lenfant, and J B Fourtillan
June 1991, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!